Teacher Retirement System of Texas Acquires Shares of 9,543 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Teacher Retirement System of Texas bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 9,543 shares of the company's stock, valued at approximately $768,000.

Several other large investors have also recently bought and sold shares of PRCT. Raleigh Capital Management Inc. acquired a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $32,000. Signaturefd LLC boosted its stake in PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after purchasing an additional 145 shares during the period. IFP Advisors Inc bought a new position in PROCEPT BioRobotics during the 4th quarter worth about $58,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at about $64,000. Finally, Arcadia Investment Management Corp MI bought a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $64,000. Institutional investors own 89.46% of the company's stock.

Insider Activity at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares of the company's stock, valued at $9,875,374.20. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,455 shares of company stock worth $368,322. Company insiders own 17.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Truist Financial reissued a "buy" rating and issued a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. Morgan Stanley reduced their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics has an average rating of "Moderate Buy" and a consensus price target of $94.29.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT traded down $2.96 on Thursday, hitting $54.78. 1,394,060 shares of the stock were exchanged, compared to its average volume of 758,038. The business's fifty day moving average is $64.22 and its 200 day moving average is $77.19. PROCEPT BioRobotics Co. has a 52 week low of $45.56 and a 52 week high of $103.81. The company has a market capitalization of $3.00 billion, a PE ratio of -28.09 and a beta of 1.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. Research analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).